Spot Trading L.l.c buys $3,244,184 stake in BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) : Spot Trading L.l.c scooped up 24,110 additional shares in BioMarin Pharmaceutical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 31,975 shares of BioMarin Pharmaceutical which is valued at $3,244,184.BioMarin Pharmaceutical makes up approximately 0.43% of Spot Trading L.l.c’s portfolio.

Other Hedge Funds, Including , Nippon Life Insurance Co reduced its stake in BMRN by selling 6 shares or 0.07% in the most recent quarter. The Hedge Fund company now holds 9,055 shares of BMRN which is valued at $918,720. BioMarin Pharmaceutical makes up approx 0.02% of Nippon Life Insurance Co’s portfolio. Huntington National Bank sold out all of its stake in BMRN during the most recent quarter. The investment firm sold 247 shares of BMRN which is valued $24,228.Cornerstone Advisors boosted its stake in BMRN in the latest quarter, The investment management firm added 13 additional shares and now holds a total of 950 shares of BioMarin Pharmaceutical which is valued at $93,186. BioMarin Pharmaceutical makes up approx 0.09% of Cornerstone Advisors’s portfolio.Parametrica Management Ltd boosted its stake in BMRN in the latest quarter, The investment management firm added 3,898 additional shares and now holds a total of 6,507 shares of BioMarin Pharmaceutical which is valued at $608,925. BioMarin Pharmaceutical makes up approx 0.87% of Parametrica Management Ltd’s portfolio.Checchi Capital Advisers reduced its stake in BMRN by selling 62 shares or 7.41% in the most recent quarter. The Hedge Fund company now holds 775 shares of BMRN which is valued at $72,525. BioMarin Pharmaceutical makes up approx 0.02% of Checchi Capital Advisers’s portfolio.

BioMarin Pharmaceutical opened for trading at $99.29 and hit $99.62 on the upside on Monday, eventually ending the session at $99.02, with a gain of 0.08% or 0.08 points. The heightened volatility saw the trading volume jump to 14,42,198 shares. Company has a market cap of $16,073 M.

On the company’s financial health, BioMarin Pharmaceutical reported $-2.61 EPS for the quarter, missing the analyst consensus estimate by $ -2.52 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.09. The company had revenue of $300.10 million for the quarter, compared to analysts expectations of $279.05 million. The company’s revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.

Many Wall Street Analysts have commented on BioMarin Pharmaceutical. Company shares were Reiterated by Stifel on Aug 5, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $107 .Company shares were Reiterated by Piper Jaffray on Aug 5, 2016 to “Overweight”, Firm has raised the Price Target to $ 120 from a previous price target of $107 .

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *